share_log
Breakings ·  Dec 31, 2024 15:56

Wedbush initiates coverage of Rocket Pharmaceuticals with an "outperform" rating and a Target Price of $32, with ongoing pipeline development and internal capacity expected to support the company's long-term growth potential.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment